In endothelial cells that form capillary-like structures in vitro a variety of genes is upregulated as we have demonstrated previously. In addition to well known genes, we also identified genes never described in endothelial cells before. Here, we report the further characterization of one selected gene called cysteine-rich motor neuron 1 (CRIM1). CRIM1 is strongly upregulated in endothelial cells during tube formation and is expressed by a variety of adherent growing cell lines whereas cell lines grown in suspension do not express CRIM1. By using antisense technology we were able to inhibit CRIM1 expression and demonstrate impaired formation of capillary-like structures in vitro in transfected endothelial cells. Furthermore, we show that CRIM1 is a glycosylated type I transmembrane protein, that accumulates at sites of close cell-to-cell contact upon stimulation. Finally, we found CRIM1 protein to be expressed by endothelial cells of the inner lining of blood vessels in vivo. Taken together our results imply a possible role of CRIM1 in capillary formation and maintainance during angiogenesis. q
Introduction
The formation of new capillaries from preexisting blood vessels is called angiogenesis and plays an important role during embryonic development and in a range of normal and pathological processes like wound healing and growth of solid tumors (Folkman, 1985; Risau, 1997) . In the past years a lot of effort has been concentrated on the identification of secreted factors that promote or inhibit angiogenic responses in vitro and in vivo (Folkman, 1997; Carmeliet and Jain, 2000) . Considerably less effort has been focused on the molecular events of endothelial cell (EC) morphogenesis during capillary assembly.
Angiogenesis does not take place in a single step, but is a complex sequential process in time and space that implies a controlled cross-talk between ECs and the surrounding environment (Risau, 1997; Sage, 1997) . ECs in preexisting vessels are activated through factors like VEGF or FGF2. The basal membrane of the vessel is lysed and cells start to proliferate and migrate into the direction of the inducing tissue. Consequently, a continuous formation of tube occurs.
At the front, capillary trunks growing in a parallel way from venular and arteriolar origin turn and fuse, thus giving rise to a functional vessel allowing for nutritive blood flow. These immature vessels are covered by pericytes that stabilize the developing vessel.
Recently, we described an experimental approach to identify genes that are upregulated or downregulated in ECs during specific steps of the angiogenic process (Glienke et al., 2000a) . Therefore, we separated proliferative events from events taking place during the actual EC tube formation. Gene expression was compared between proliferating human microvascular endothelial cells (MVEC) and MVEC cultured on a gel composed of extracted basement membrane derived from Engelbreth-Holm-Swarm sarcoma (matrigel) where MVEC stop proliferating and rapidly form capillary-like, lumen containing structures (Kubota et al., 1988) . Using the suppression subtractive hybridization technique, we identified genes that were overexpressed during endothelial capillary formation. Amongst them there was a number of genes already known to play an important role during EC morphogenesis, like PECAM-1 (DeLisser et al., 1997) , integrin a v (Gamble et al., 1993; Friedlander et al., 1995) , PAI-1 (Schnaper et al., 1995) and MMP-1, 2 (Hiraoka et al., 1998; Brooks et al., 1996) . Furthermore, we found new genes that might play a role during in vitro capillary tube formation.
Here, we describe the further characterization of one selected gene called je68, recently published as cysteinerich motor neuron 1 (CRIM1; Kolle et al., 2000) and present evidence for its involvement in EC morphogenesis in vitro. The cellular localization and in vivo expression of the corresponding protein je68/CRIM1 is shown.
Results

Je68 is upregulated on tubular MVEC
Human microvascular endothelial cells (MVEC) cultured on matrigel form capillary-like structures (Fig. 1B) in contrast to cells cultured on collagen coated dishes that, when confluent, show a 'cobble stone' like morphology (Fig. 1A) . Using the suppression subtractive hybridisation technique (SSH; Diatchenko et al., 1996) , a subtracted cDNA library was obtained enriched for genes upregulated in tube forming MVEC. In a differential hybridization experiment several differentially expressed clones have been identified and their regulated expression was confirmed using semi-quantitative RT-PCR (Glienke et al., 2000a) . One of these clones was selected for further characterization. This clone was called je68.
In order to determine the size of the full-length je68 transcript a northern blot experiment was performed on total RNA derived from proliferating MVEC and MVEC on matrigel with a je68 specific probe. As shown in Fig. 1C , a single specific band was detected with a size of ,6 kb. Furthermore, the substantial upregulation of je68 mRNA in MVEC cultured on matrigel compared to proliferating MVECs was confirmed. This difference in expression was quantified by comparative multiplex RT-PCR (Pilarsky et al., 1998 ) using a je68 specific primer pair and a pair of primers specific for 23 kD highly basic protein as internal standard (Primers see Table 1 ). As shown in Fig. 1D , je68 was found to be ,6-fold upregulated in tube forming MVEC compared to proliferating MVEC.
Isolation of full-length je68 cDNA
The SSH technique yields only Rsa I fragments of cDNAs. The complete je68 cDNA sequence was isolated by means of several rounds of 5 0 -and 3 0 -rapid amplification of cDNA end (RACE) PCR reactions with gene specific primers. Specific RACE-PCR products were cloned, sequenced and used as starting point for the next round of RACE. Finally a 6011 bp full-length cDNA of je68 was obtained, comprising 453 bp 5 0 -UTR, a single open reading frame encoding 1036 amino acids and the polyadenylation signal and site. The size of 6011 bp fits well with the expected size of je68 from the northern blot experiment. By performing electronic PCR (Schuler, 1998) , the genomic localization of the je68 gene could be assigned to chromosome 2p21. In order to identify related sequences, a BLAST search was performed and we found je68 to be identical to a recently published gene, cysteine-rich motor neuron 1 (CRIM1; GenBank accession no. AF167706; Kolle et al., 2000) . Furthermore, we identified a homologous sequence in mouse (GenBank accession no. AF168680) and a potential C. elegans homolog, B0024.14 (Wilson et al., 1994) .
Je68/CRIM1 encodes a C-rich transmembrane protein with 6 vWC domains
The je68/CRIM1 cDNA sequence contains an ORF Fig. 1 . Cell culture systems and differential expression of je68/CRIM1. In (A), MVEC cultured on collagen I coated plastic are shown with the typical 'cobblestone' morphology. In (B), MVEC cultured on matrigel for 7 h are shown forming the typical capillary-like structures. Bar, 125 mm. In (C), a Northern blot experiment on mRNA derived from proliferating and tube forming MVEC shows substantial upregulation of je68/CRIM1 in tube forming ECs. In (D), this upregulation was confirmed and quantified using comparative multiplex RT-PCR (n ¼ 6, mean^SD, *P , 0:01 with respect to matrigel). Je68/CRIM1 appeared to be upregulated by a factor of ,6. The Je68/CRIM1 protein contains a clearly predictable transmembrane domain near the C-terminus and a potential signal peptide at the N-terminus indicating a type I transmembrane protein structure with an extracellular N-terminus. For the putative extracellular part of Je68/CRIM1 5 potential N-glycosylation sites were predicted. The domain structure of Je68/CRIM1 is summarized in Fig. 2 . Near the N-terminus following the signal peptide an IGF binding protein domain was detected. Further, Je68/CRIM1 protein contains an integrin binding RGD motif (Ruoslahti and Pierschbacher, 1986) at R 314 and 6 C-rich von Willebrand factor C domains (vWC; Bork, 1993) in the extracellular region.
Expression of je68/CRIM1 mRNA in various human tissues and cell lines
In order to elucidate the tissue distribution of je68/ CRIM1, a hybridization probe was generated by PCR using a je68/CRIM1 specific primer pair. The je68/CRIM1 probe was hybridized to a human 12-lane multi-tissue northern blot (Clontech). The strongest signal was detected in placenta, followed by kidney, heart and skeletal muscle (Fig. 3A) . Weaker expression was found in the lung and a faint band was seen in spleen, liver and small intestine. In colon, thymus, brain and peripheral blood leukocytes no signal was detected.
Since je68/CRIM1 is expressed and regulated by MVEC and strongest expression was found in tissues with a high content of endothelial cells like placenta, kidney and lung, the question arose whether je68/CRIM1 might be specific for endothelium. To check whether je68/CRIM1 is also expressed in other cell types, a northern blot experiment was performed with mRNA derived from various different cell lines. Fig. 3B shows a strong expression of je68/CRIM1 in MVEC, T47D, primary fibroblasts and large cell lung carcinoma (LCLC) cells. Je68/CRIM1 appeared to be absent in the lymphoblast cell line TF-1 and the myeloma cell line U266. In conclusion, je68/CRIM1 is not specifically expressed in endothelial cells and a strong je68/ Fig. 2 . Protein domain structure is depicted for je68/CRIM1. The protein has a N-terminal signal peptide followed by an IGF binding protein like domain, a RGD motif, six von Willebrand factor C domains, a transmembrane domain and five potential N-glycosylation sites in the extracellular part. This points to a type I transmembrane protein orientation. The RGD motif is conserved between human and mouse je68/CRIM1. Fig. 3 . Expression pattern of je68/CRIM1. In (A), a human 12-lane multiple tissue Northern blot was probed with a je68/CRIM1 specific probe. Je68/ CRIM1 shows highest expression in placenta and kidney followed by heart skeletal muscle and lung, low expression was detected in spleen, liver and small intestine. In (B), in a Northern blot experiment je68/CRIM1 expression was analyzed in a variety of cell lines. Je68/CRIM1 is expressed in all adherent growing cell lines, but is absent from cell lines grown in suspension like the lymphoblast cell lines TF-1 and U266.
CRIM1 expression was found in all adherent growing cells tested. Whereas cells grown in suspension did not show any je68/CRIM1 expression.
Antisense mediated down regulation of je68/CRIM1 mRNA in MVEC leads to inhibition of tube formation on matrigel
To detect a functional role for je68/CRIM1, an antisense oligonucleotide with a thio-phosphate backbone was designed, specific for the fourth vWC domain of je68/ CRIM1. It was called CRIM1as. As a negative control, a randomized oligonucleotide (N 23 ) of the same length and chemistry, called GBC, was used in all experiments. Optimal delivery conditions were established for human umbilical vein endothelial cells (HUVEC). The efficiency of CRIM1as to reduce specifically the amount of je68/ CRIM1 mRNA was determined by comparative multiplex RT-PCR. As shown in Fig. 4A , CRIM1as significantly suppresses je68/CRIM1 expression compared to the control GBC by ,80%.
Proliferation tests using transfected and untransfected HUVEC were performed in order to check for cytotoxicity of the oligonucleotides, changes in the rate of adhesion to collagen I and cell growth of transfected cells. Under the conditions used, the antisense oligos did not exhibit significant cytotoxicity and the adhesion rate of transfected HUVEC to collagen I was unaltered. As illustrated in Fig.  4B , the proliferation rate of GBC or CRIM1as transfected HUVEC was not significantly changed to that of untransfected cells.
Untransfected, GBC and CRIM1as transfected HUVEC of the same transfection experiment were subjected to the tube formation assay on matrigel. As expected, both untransfected and GBC transfected HUVEC formed an extended network of capillary-like structures within 7 h, leaving only a few single cells not involved in tube formation ( Fig. 5A, B) . As can be seen in Fig. 5C , HUVEC transfected with CRIM1as showed severe defects in tube formation compared to controls. Much less cells are engaged in building up intercellular connections and no extended network is formed. More than half of the cells remain as single, rounded cells not connected to their neighbours.
Tube formation was quantified by counting the branching points of capillary-like structures per visual field. As illustrated in Fig. 5D , CRIM1as transfected HUVEC form ,5 times less branched tubes compared to untransfected or GBC transfected cells. Taken together je68/CRIM1 is important for endothelial cell tube formation on matrigel.
Generation of a je68/CRIM1-specific antibody
In order to generate a je68/CRIM1 specific antibody, we expressed and purified a protein fragment of the extracellular part of je68/CRIM1. This protein fragment was used to immunize mice and the resulting polyclonal serum was tested for specificity. As shown in Fig. 6A , we were able to generate a polyclonal mouse serum that specifically detects a band of ,130 kDa in MVEC which is absent in je68/CRIM1 non-expressing TF-1 cells. This band disappears when the serum is preincubated with the je68/ Fig. 4 . Je68/CRIM1 downregulation using antisense oligonucleotides. In (A), je68/CRIM1 mRNA knock down is shown using comparative multiplex RT-PCR for quantification (n ¼ 6, mean^SD, *P , 0:01 with respect to w/o oligo and GBC). The je68/CRIM1 specific antisense oligo, CRIM1as, leads to a substantial down regulation of je68/CRIM1 mRNA compared to untreated and control oligo (GBC) transfected HUVEC. In (B), transfection with CRIM1as oligonucleotide does not lead to a change in HUVEC proliferation compared to untreated or control transfected (GBC) HUVEC (n ¼ 4, mean^SD).
CRIM1 protein fragment used for immunization. The size of the detected je68/CRIM1 band is slightly larger than the calculated ,114 0kDa for the predicted je68/CRIM1 protein. Since je68/CRIM1 contains five potential N-glycosylation sites, we speculated whether the difference in size is due to glycosylation of the native protein. To test this, we performed a deglycosylation experiment with MVEC lysates using N-Deglycosydase F. As shown in Fig. 6B in the deglycosidase treated sample the je68/CRIM1 band shifted from ,130 kDa close to the predicted protein size of ,114 kDa.
Je68/CRIM1 localization in MVEC
Based on the structure of the je68/CRIM1 protein and the glycosylation pattern, we expected je68/CRIM1 to be a type 1 transmembrane protein with a N-terminal extracellular domain. To test this, we performed immunofluorescent staining of transfected COS-1 cells and primary MVEC. To demonstrate the specificity of our je68/CRIM1 polyclonal mouse serum we transiently transfected COS-1 cells either with an expression vector encoding je68/CRIM1-myc-His fusion protein or with an expression construct encoding je68/CRIM1-EGFP. As shown in Fig. 7A -D, we found je68/CRIM1 colocalizing with calnexin ( Fig. 7D ) a specific marker for endoplasmic reticulum in transfected COS-1 cells. Je68/CRIM1 localization was identical in the respective cells when detected either with je68/CRIM1 antiserum (Fig. 7A) , anti c-myc antibody (Fig. 7C ) or GFP staining (Fig. 7B) . Furthermore the je68/CRIM1 polyclonal antiserum did not yield to any detectable background staining.
To test whether naturally occuring Je68/CRIM1 also localizes to the endoplasmic reticulum, we stained primary MVEC with the je68/CRIM1 antiserum (Fig. 7E) . As shown in Fig. 7E and F, je68/CRIM1 colocalized with calnexin in MVEC without obvious accumulation of je68/CRIM1 at the plasma mebrane. In order to detect minimal amounts of je68/CRIM1 presented at the plasma membrane, we stained living, unfixed MVEC using the je68/CRIM1 antiserum. Under these conditions MVEC partially detach from the surface and show a rounded appearance. As shown in Fig.  7G , we were able to detect only very faint signals over background on the surface of unfixed MVEC. As a control for membrane staining on unfixed MVEC we used anti CD31/PECAM-1 antibodies, as shown in Fig. 7H . Further we tested whether we can induce je68/CRIM1 transfer to the plasma membrane by MVEC stimulation. MVEC were stimulated using 100 ng/ml lipopolysaccharide (LPS, SIGMA) for 4 h followed by je68/CRIM1 staining. As shown in Fig. 8A , we now were able to detect je68/ CRIM1 accumulation at specific sites of the plasma membrane in contrast to the calnexin control showing an ER staining also under LPS stimulation (Fig. 8B) . Particularly sites of close MVEC cell-to-cell contact showed increased plasma membrane localization of je68/CRIM1 (Fig. 8C) . No such change in protein localization was detected for calnexin. A typical plasma membrane staining under LPS stimulation is shown in Fig. 8D using anti CD31/ PECAM1 antibodies for detection.
Je68/CRIM1 protein is expressed in blood vessels in vivo
The primary MVEC used in this study were prepared from human foreskin. To elucidate whether je68/CRIM1 is expressed by endothelial cells in vivo, we performed immunohistological experiments on successive cryosections of human foreskin. In Fig. 9A , B endothelial cells were stained using a specific antibody against CD31/ PECAM-1. As shown in Fig. 9C , D we detected je68/ CRIM1 protein in endothelial cells in the stroma of the dermis and in the epithelial cells of the epidermis. At higher magnification (Fig. 9B, D, F) je68/CRIM1 staining was associated with the inner lining of CD31 positive blood vessels. These signals disappeared when the je68/CRIM1 antiserum was preincubated with the je68/CRIM1 protein fragment (Fig. 9E, F) . So je68/CRIM1 is expressed in blood vessels of the human foreskin in vivo but also in the epithelial cells of the epidermis.
Discussion
In a previous study, we reported the identification of genes that are differentially expressed in endothelial cells during capillary morphogenesis in vitro compared to proliferating endothelial cells (Glienke et al., 2000a) . Here, we further characterized one gene called je68 that appeared to be overexpressed in tube forming endothelial cells compared to proliferating MVEC. During the course of our work that gene was published by another group as cysteine-rich motor neuron 1, CRIM1 . This gene has been shown to be expressed in motor neurons during maturation and during ocular development in a variety of epithelial cells in vivo Lovicu et al., 2000) .
Here we demonstrate je68/CRIM1 expression and regulation by MVEC implying a possible function of this gene during capillary formation in vitro. By inhibiting je68/ CRIM1 expression in HUVEC, we could show that je68/ CRIM1 plays an important role in tube formation on matrigel. The extent of cord like structures and the number of branching points was significantly decreased when a je68/ Fig. 6 . Generation of a je68/CRIM1 specific polyclonal antiserum. (A), a fragment of the extracellular part of je68/CRIM1 was expressed, purified and used to immunize mice that were selected for low-signal preserum. The polyclonal serum of the selected mouse detected a clear, single band in the je68/CRIM1 positive MVEC which was absent from the je68/CRIM1 negative TF-1. This signal disappeared when the antiserum was preincubated with je68/CRIM1 protein fragment used for immunization. The size of this band was ,130 kDa. (B), to check whether je68/CRIM1 is glycosylated, we performed a deglycosylation experiment. The band in the N-deglycosydase F treated sample shifted to a moleclular weight of ,115-120 kDa, whereas the sample without N-deglycosydase F remains at ,130 kDa. CRIM1 antisense oligonucleotide was given. Interestingly je68/CRIM1 antisense treated HUVEC still adhere to matrigel but remain with a rounded cell shape and do not build up intercellular connections. This implies a possible role for je68/CRIM1 in cell attachment or alternatively in cell-tocell contact formation. This assumption is supported by the following observations. We found je68/CRIM1 to be expressed in a variety of adherent growing cell lines but je68/CRIM1 was virtually absent from cells grown in suspension. Furthermore we identified a RGD motif, a so called cell attachment sequence (Ruoslahti and Pierschbacher, 1986) , in the putative extracellular domain of je68/CRIM1. This RGD motif is conserved throughout human and mouse je68/CRIM1 (Fig. 2) . We and others have shown previously that MVEC upregulate several integrins when grown on matrigel (Gamble et al., 1993) . Integrins are known to bind the RGD motif and play an important role in cell attachment (Buck and Horwitz, 1987) . In addition je68/CRIM1 contains six vWC domains known to play a role in mediating proteinprotein binding (Bork, 1993) .
Je68/CRIM1 antisense treated HUVEC showed no inhibition of adhesion to collagen I and matrigel. This insinuates that je68/CRIM1 might be involved rather in cell-to-cell contact formation. To further investigate je68/CRIM1 expression and localization we developped a je68/CRIM1 specific antibody. Using this antibody we could show that je68/CRIM1 is glycosylated in endothelial cells. Together with the protein domain structure shown in Fig. 2 , we propose je68/CRIM1 to be a type 1 transmembrane protein sitting in the plasma membrane with an extracellular Nterminus. We then performed immunofluorecence staining of je68/CRIM1 in primary MVEC and found je68/CRIM1 colocalizing with the endoplasmic reticulum marker calnexin. Only minor amounts of je68/CRIM1 were detectable at the cell surface. Stimulation of MVEC with LPS lead to accumulation of je68/CRIM1 at sites of close cell-to-cell contact. This fits well with the reported expression pattern of CRIM1 in developing motor neurons and occular tissues Lovicu et al., 2000) where also during invasion new cell-to-cell contacts have to be established.
The formation of close cell contacts between endothelial cells in vivo is a prerequisite for the establishment of functional capillaries during the angiogenic process (Sage, 1997) . In order to elucidate whether je68/CRIM1 might serve such a function in vivo, we performed immunohistological analysis of sections of human foreskin. We detected Fig. 7 . Cellular localization of je68/CRIM1. COS-1 cells were transiently transfected to express je68/CRIM1-myc-His fusion protein or je68/ CRIM1-EGFP. Je68/CRIM1 localization was detected either by immunofluorescence staining using je68/CRIM1 antiserum (A), anti myc antibody (C) or GFP staining (B). All three staining procedures showed je68/CRIM1 to be located intracellularly, probably in the endoplasmic reticulum. This localization was further confirmed by staining COS-1 cells using a calnexin antibody to visualize the endoplasmic reticulum (D). To investigate the localization of naturally occuring je68/CRIM1, MVEC were stained either with je68/CRIM1 antiserum (E) or calnexin (F) showing a colocalization of signal in the endoplasmatic reticulum. In (G) and (H) unfixed MVEC were stained using je68/CRIM1 antiserum and anti CD31 antibody respectively to detect protein on the extracellular part of the plasma membrane. Bar, 25 mm. Fig. 8 . In LPS stimulated MVEC je68/CRIM1 accumulates at the plasma membrane. In (A) LPS stimulated MVEC were stained using je68/CRIM1 antiserum, showing specific staining at specific sites of the plasma membrane of these MVEC. In a control experiment using anti calnexin antibody staining of LPS stimulated MVEC was restricted to the endoplasmatic reticulum as shown in (B). Plasma membrane localization of je68/ CRIM1 was investigated at higher magnification in (C) and arrow heads indicate je68/CRIM1 accumulation at sites of close cell-to-cell contact. As a control for a typical plasma membrane staining on LPS stimulated MVEC anti CD31 antibody was used (D). Bar, 25 mm. je68/CRIM1 staining in endothelial cells associated with the inner lining of blood vessels. This result is further corroborated by the reported expression of CRIM1 in the developing blood vessels aligned along the inner limiting membrane of the neural retina in mouse embryos at day E18.5 (Lovicu et al., 2000) .
A number of other proteins, like Chordin or Noggin contain a cluster of vWC domains similar to je68/CRIM1. These proteins were shown to bind members of the TGF-b and BMP family of growth factors (Francois et al., 1994; Sasai et al., 1994; McMahon et al., 1998) . In previous reports, it was speculated whether CRIM1 might also bind to growth factors of the IGF, TGF-b or BMP class .
In summary, je68/CRIM1 is important for endothelial cell tube formation in an in vitro model of angiogenesis. Je68/ CRIM1 is a type 1 transmembrane protein that is presented at the cell surface in response to cell stimulation and is located at sites of close cell-to-cell contacts. Furthermore je68/CRIM1 is expressed in mature and developing blood vessels in vivo, implying a possible role in blood vessel formation and stabilization during angiogenesis.
Experimental procedures
RNA preparation for RT-PCR and northern
Total RNA was prepared from cells using RNeasy kit (Qiagen) according to manufacturers recommendations. The amount of total RNA was determined by OD measurement and its purity was checked by absorbance quotient: OD 260/280 . 1.8.
Northern blot
Twenty micrograms of each total RNA was electrophoresed on a 1% agarose/formaldehyde gel, photographed, capillary blotted onto nylon membranes and UV crosslinked. A specific cDNA probe labeled with 32 P-dATP using a random primer labeling kit (STRATAGENE). The filter was hybridized in ExpressHyb (CLONTECH) for 18 h at 688C and washed extensively at high stringency. Filter was exposed to X-ray film (KODAK).
Comparative multiplex RT-PCR
Reverse transcription was performed using Ready-to-go T-Primed first strand Kit (PHARMACIA BIOTECH) according to manufacturers recommendations. For each total RNA 3.3 mg were reverse transcribed in a total volume of 33 ml. To quantify differential gene expression, comparative multiplex RT-PCR was performed as described elsewhere (Pilarsky et al., 1998) . The primers used are given in Table 1 . The forward primers were labeled at the 5 0 -end with a fluorescence marker, FAM for je68/CRIM1 and JOE for the internal standard, 23 kD highly basic protein (GenBank Acc. No: AF039843). The samples were Fig. 9 . Je68/CRIM1 is expressed in ECs of blood vessels in vivo. Cryo-sections of human forskin were stained either with an EC marker, PECAM-1/CD31, or with the je68/CRIM1 specific antiserum. As shown in (A), CD31 highlights blood vessels in the dermis and epidermis. The je68/CRIM1 antiserum shows the same staining pattern in the dermis, but also stains the epithelial cells of the epidermis (C). This staining disappears when the je68/CRIM1 antiserum is preincubated with the je68/CRIM1 protein fragment used for immunization (E,F). At a higher magnification we detected the je68/CRIM1 staining (D) to be located with the CD31 positive EC (B) at the inner lining of blood vessels (arrow heads). Bar, 250 mm (A,C,E), 125 mm (B,D,F).
analyzed and quantified using GenScan software version 2.1 (PERKIN ELMER). The PCR products were checked for correct size according to the size standard GS-350 TAMRA (PERKIN ELMER) included in each sample and the amount of product was quantified by measuring the fluorescence intensity. For further analysis the area below the curve of the fluorescence peak for each PCR product was integrated.
Je68/CRIM1 expression constructs
Je68/CRIM1 full length was cloned into the eukaryotic expression vectors pcDNA3.1 myc-His (Invitrogen) and pEGFP-N3 (Clontech) in frame to produce je68/CRIM1-myc-His fusion protein or je68/CRIM1-EGFP, respectively with tags at the C-terminus of je68/CRIM1 using restriction sites Kpn I at the 5 0 -end and Apa I at the 3 0 -end. The fragment was amplified by PCR from total cDNA derived from MVEC using the primers je68fl5 and je68fl3. The PCR product was digested with Kpn I and Apa I and ligated either in pcDNA3.1 or pEGFP. The resulting vector constructs were used in transient transfections of COS-1 cells using a standard Lipofectamin (Invitrogen) protocol.
To produce enough protein for the immunization of mice, a fragment of the je68/CRIM1 N-terminus was cloned into the prokaryotic expression vector pQE30 in frame with an N-terminal His tag. The fragment comprised amino acid D 41 to E 240 with an expected molecular mass of ,22 kDa. The fragment was amplified by PCR from total cDNA derived from MVEC using the primers je68pQE30F and je68pQE30R. The PCR product was digested with BamH I and Kpn I and ligated in pQE30. The resulting vector construct was transformed in TOP10F 0 (Invitrogen) E. coli cells. The fusion protein was expressed and purified as described for another protein elsewhere (Glienke et al., 2000b) . All expression constructs have been sequenced prior to use to check for correct insert.
Cell culture
Primary human microvascular endothelial cells (MVEC) and human umbilical vein endothelial cells (HUVEC) were prepared as described (Piossek et al., 1999) . MVEC/ HUVEC were cultured in flasks coated with 10 mg/ml collagen I (Serva) and in M199 medium (BIOCHROM) containing 10% fetal calf serum, 10% human serum, 2 mM glutamax, penicilin (100 m/ml), streptomycin (100 mg/ml), ascorbic acid (1.27 mM), pyruvic acid (1 mM), 1% non-essential amino acids (BIOCHROM), 6 mg/ml endothelial growth factor from bovine brain (Sigma) and 7.5 mg/ml heparin (Sigma).
To induce the differentiating phenotype, MVEC were cultured on a gel composed of extracellular matrix proteins, matrigel (BECKTON DICKINSON). Matrigel was diluted 1 1 1 with M199 medium and the gel was poured at 60 ml/ cm 2 in the cold. The gel solidified for 30 min at 378C and MVEC were seeded at 1 £ 10 4 cells/cm 2 . MVEC on matrigel were cultured in full medium.
MVEC/HUVEC were passaged by trypsin digestion (0.02% trypsin, 0.01% EDTA in PBS without bivalent ions).
Antisense transfection
The antisense oligonucleotides used in this work were stabilized by a thio-phosphate backbone and produced by Ribozyme Pharmaceuticals Inc. The antisense oligonucleotides used are 23 mers. For all antisense experiments human umbilical vein endothelial cells (HUVEC) from fourth to fifth passage were used. For each transfection 2 £ 10 6 HUVEC were seeded in a collagen coated 75 cm 2 flask and grown overnight in full serum containing medium. On the next day the medium was removed and the cells were washed two times with PBS to remove remaining serum. Each transfection was performed in a total volume of 15 ml M199 medium containing 1% human serum, 0.4 mM antisense oligonucleotide and 1 mg/ml transfection agent RPI9650 (Ribozyme Pharmaceutical Inc.). After 7 h of incubation the transfection medium was removed, the cells were washed with PBS and grown overnight in full serum containing medium. The other day the cells were trypsinized, counted and subjected to the tube formation test on matrigel, a proliferation test using full serum containing medium and comparative multiplex RT-PCR to monitor down regulation of the gene of interest. The sequence of the je68/CRIM1 specific antisense oligonucleotide, called CRIM1as, is 5 0 -UACAGAUCAACCUUUUC-GGCCUU-3 0 . As a control we used a randomized GBC oligonucleotide of the same chemistry with the sequence N 23 .
Proliferation test with transfected endothelial cells
Thirty thousand cells per well were plated in a 24-well plate (COSTAR) in full M199 medium. The cells were allowed to attach for 2 h then the medium was changed to fresh M199 full medium. After 3 days of culture 1:100 (v/v) AlamarBlue (BIOSOURCE Int.) was added to the cells and the cells were incubated for 2 h at 378C. Then the fluorimetric change was mesured using a Cytofluor 2350 reader (MILLIPORE). All proliferation experiments were performed at least three times as separate experiments.
Quantification of tube formation on matrigel by endothelial cells
Matrigel was diluted 1 1 1 in M199 medium and the gel was poured at 60 ml/cm 2 on six-well plates in the cold. The gel solidified within 30 min at 378C and endothelial cells were seeded at 1 £ 10 4 cells/cm 2 . For each transfection experiment three wells were prepared. Endothelial cells on matrigel were cultured in full medium for 7 h. Three randomly chosen visual fields for each well were photo-graphed. For a quantification, the number of crossings of capillary like structures per visual field was counted.
Generation of Je68/Crim1 specific antiserum
Over a period of 6 weeks, Balb/c mice were immunized in weekly intervals with a purified fragment of recombinant je68/CRIM1 protein by 25 mg/i.p. injection in TiterMax adjuvant (ALEXIS Corp.). Two weeks after the last immnization, the animals were boosted with the same amount of antigen. Three days after the final injection, the animals were exsanguinated.
Deglycosylation
Cells were lysed in 1 £ RIPA, homogenized using a 18 G needle syringe and centrifuged to pellet cellular debris. Fifty micrograms cleared protein lysate was used per sample. Deglycosylation reaction and control were performed using N-Glycosidase F Deglycosylation Kit (Boehringer Mannheim) according to manufacturers recommendations. The complete samples were subjected to SDS-PAGE and analyzed by Western blot using the CRIM1 specific polyclonal antiserum.
Immunohistology/Immunofluorescence
Cryo sections were fixed for 10 min at 2208C in 1:1 acetone : methanol. The slides were washed for 5 min in TBS and blocked for 30 min with goat serum (Vector Lab. Inc.) 1:50 in TBS. The sections were incubated for 30 min with first antibody, washed in TBS, incubated for 10 min with 3% H 2 O 2 in TBS and washed again in TBS. The second antibody was incubated for 30 min and the slides were washed in TBS. Detection was performed using ABC reagent (Vector Lab. Inc.) and nuclei were stained using haemalaun (Merck KGaA). For immunohistology the je68/CRIM1 polyclonal antiserum was used 1:50, the anti CD31 antibody (PharMingen) 1:250 and the second antibody goat anti mouse biotin coupled (Vector Lab. Inc.) 1:200. Antibodies were diluted in 2% FCS in TBS.
For immunofluorescence 80,000 cells were spread per chamber on four chamber slides and allowed to adhere over night. Cells were washed twice in PBS and fixed at 2208C for 10 min in 1:1 acetone : methanol. The slides were washed in PBS, blocked with goat serum 1: 50 for 30 min, washed and incubated with first antibody for 30 min. The slides were washed several times in PBS and incubated with second antibody for 30 min. Then the slides were washed for several times, fixed again in 1% PFA/PBS and mounted using Vectashield (Vector Lab. Inc.). For immunofluorescence the je68/CRIM1 polyclonal antiserum was used 1:50, the anti CD31 antibody (PharMingen) 1:250, the anti calnexin antibody (Stressgene) 1:200 and the second antibody goat anti mouse FITC labeled (Jackson ImmunoResearch Lab. Inc.) 1:50. Antibodies were diluted in 2% FCS in PBS.
